Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.64M | 23.92M | 18.46M | 14.26M | 11.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.78M | 51.58M | 47.67M | 42.26M | 38.96M |
| Operating Income | -51.78M | -51.58M | -47.67M | -42.26M | -38.96M |
| Income Before Tax | -44.52M | -50.17M | -53.02M | -62.28M | -42.83M |
| Income Tax Expenses | 66.00K | -60.00K | -60.00K | -60.00K | -60.00K |
| Earnings from Continuing Operations | -44.58 | -50.11 | -52.96 | -62.22 | -42.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.58M | -50.11M | -52.96M | -62.22M | -42.77M |
| EBIT | -51.78M | -51.58M | -47.67M | -42.26M | -38.96M |
| EBITDA | -51.49M | -51.29M | -47.40M | -42.02M | -38.77M |
| EPS Basic | -1.36 | -1.83 | -3.01 | -3.88 | -3.62 |
| Normalized Basic EPS | -0.85 | -1.15 | -1.88 | -2.43 | -2.26 |
| EPS Diluted | -1.55 | -2.02 | -3.17 | -3.89 | -3.62 |
| Normalized Diluted EPS | -0.85 | -1.14 | -1.88 | -2.43 | -2.26 |
| Average Basic Shares Outstanding | 146.44M | 119.56M | 91.53M | 66.97M | 48.89M |
| Average Diluted Shares Outstanding | 148.53M | 121.64M | 93.16M | 66.97M | 48.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |